Investigational drug · Phase 3
KLH-2109
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Menorrhagia, Uterine Fibroids, Endometriosis.
Phase 3Last checked: Nov 19, 2026Latest source record: May 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
8
Any phase or sponsor naming "KLH-2109"
First trial start
2025
Jun 9, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KLH-2109", any sponsor or status.
Conditions studied
As listed on its trial records.
- Menorrhagia
- Uterine Fibroids
- Endometriosis
Approved drugs for the same conditions: Endometriosis · Uterine fibroids · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "KLH-2109" as an intervention, largest first.
- A Clinical Study of KLH-2109 in Patients With EndometriosisPivotal-lookingActive, not recruiting
Kissei Pharmaceutical Co., Ltd.Industry
NCT07015268 · 288 participants (planned) · Start Jun 9, 2025 · Primary completion Nov 2027
Drug: KLH-2109; Leuprorelin acetate · For: Endometriosis
Sites: Multiple Locations, Japan
- A Clinical Study of KLH-2109 in Uterine Fibroids Patient With MenorrhagiaPivotal-lookingCompleted
Kissei Pharmaceutical Co., Ltd.Industry
NCT05440383 · 287 participants · Start Oct 11, 2022 · Primary completion Aug 21, 2024
Drug: KLH-2109; Leuprorelin · For: Uterine Fibroids (MeSH Heading: Leiomyoma)
Sites: Multiple Locations, Japan
- to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and MenorrhagiaPivotal-lookingRecruiting
JW PharmaceuticalIndustry
NCT07378098 · 254 participants (planned) · Start Feb 3, 2026 · Primary completion Mar 31, 2028
Drug: KLH-2109+ Leurprorelin acetate Placebo; KLH-2109 Placebo + Leurprorelin acetate · For: Menorrhagia; Uterine Fibroids
Sites: Seoul, South Korea
- A Randomized, Placebo-controlled, Double-blind Study of KLH-2109 in Patients With Endometriosis (2)Pivotal-lookingCompleted
Kissei Pharmaceutical Co., Ltd.Industry
NCT01533532 · 100 participants
Drug: KLH-2109; KLH-2109 and 2 more · For: Endometriosis
Sites: Tokyo and Other Japanese City, Japan
- A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and PainPivotal-lookingCompleted
Kissei Pharmaceutical Co., Ltd.Industry
NCT05445167 · 89 participants · Start Oct 11, 2022 · Primary completion Feb 16, 2024
Drug: KLH-2109; Placebo · For: Uterine Fibroids (MeSH Heading: Leiomyoma)
Sites: Multiple Locations, Japan
Kissei Pharmaceutical Co., Ltd.Industry
NCT01395940 · 20 participants (planned)
Drug: KLH-2109; KLH-2109 · For: Endometriosis
Sites: Tokyo and Other Japanese City, Japan
Kissei Pharmaceutical Co., Ltd.Industry
NCT01629420 · 20 participants
Drug: KLH-2109; KLH-2109 · For: Endometriosis
Sites: Tokyo and Other Japanese City, Japan
Kissei Pharmaceutical Co., Ltd.Industry
NCT02778919 · Start May 9, 2016 · Primary completion Mar 23, 2018
Drug: KLH-2109; Placebo and 1 more · For: Endometriosis
Sites: Multiple Locations, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas.
Dababou S, Garzon S, Laganà AS, et al. · Expert Opin Investig Drugs 2021
- A peek into the drug development scenario of endometriosis - A systematic review.
Goenka L, George M, Sen M · Biomed Pharmacother 2017
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.